Press Releases April 8, 2026 08:00 PM

AMN Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026

AMN Healthcare schedules Q1 2026 earnings call and provides investor resources.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
AMN

AMN Healthcare Services, Inc. announced its first quarter 2026 earnings conference call to be held on May 7, 2026, along with the release of its financial results and second quarter outlook. The company provides workforce solutions for healthcare and reaches millions of patients through its vast network.

AMN Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026
AMN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings call scheduled for May 7, 2026, following the release of Q1 financial results and Q2 outlook.
  • AMN Healthcare is a leading provider of total talent solutions in the healthcare workforce sector, serving over 2,300 healthcare systems nationwide.
  • The company leverages integrated workforce technologies to address healthcare staffing challenges across the industry.

DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook on Thursday, May 7, 2026, at 5:00 p.m. Eastern Time. On the same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time.

A live webcast of the call can be accessed through this webcast link, which also will be available on AMN Healthcare’s investor relations website. Interested parties may participate live via telephone by registering at this conference call link. Please follow the link and register with a valid e-mail address. A PIN will be provided to you with dial-in instructions. If you lose track of these details, please re-register at the conference call link above.

Following the conclusion of the call, a replay of the webcast will be available at the Company’s investor relations website, http://ir.amnhealthcare.com.

About AMN Healthcare

AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2025, our healthcare professionals reached more than 13 million patients at more than 2,300 healthcare systems, including 93 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies. For more information, visit www.amnhealthcare.com.

The Company’s common stock is listed under the symbol “AMN” on the New York Stock Exchange. For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication (“RSS”) as routine channels to supplement the distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.

Contact:
Randle Reece
Vice President, Investor Relations and Strategy
866-861-3229
Web site: http://www.amnhealthcare.com


Risks

  • Potential variability or challenges in healthcare staffing demand could impact financial performance.
  • Economic or regulatory changes in the healthcare sector may affect AMN's operations and growth prospects.
  • Execution risk associated with integrating technology solutions with workforce offerings could influence competitive position.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026